A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC). The trial included Phase Ib escalation and expansion parts and a randomised Phase II part ve...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of cancer Vol. 129; no. 6; pp. 965 - 973
Main Authors:	Macaulay, Valentine M, Lord, Simon, Hussain, Syed, Maroto, José Pablo, Jones, Robert Hugh, Climent, Miguel Ángel, Cook, Natalie, Lin, Chia-Chi, Wang, Shian-Shiang, Bianchini, Diletta, Bailey, Mark, Schlieker, Laura, Bogenrieder, Thomas, de Bono, Johann
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 05.10.2023
Subjects:	Antibodies, Neutralizing Antineoplastic Combined Chemotherapy Protocols - adverse effects Castration Humans Insulin-like growth factor I Insulin-like growth factors Male Metastases Metastasis mRNA Nitriles - therapeutic use Prostate cancer Prostate-specific antigen Prostatic Neoplasms, Castration-Resistant - pathology PTEN protein Treatment Outcome
ISSN:	0007-0920, 1532-1827, 1532-1827
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!